radiogenomics in active surveillance how can we integrate mpmri and genomics to monitor pca
Published 4 years ago • 554 plays • Length 11:04Download video MP4
Download video MP3
Similar videos
-
11:04
radiogenomics in active surveillance how to integrate mpmri and genomics to monitor prostate cancer
-
1:58
integrated diagnostics and patient selection for active surveillance and treatment
-
12:19
active surveillance 2022: who qualifies, who does not and how should it be monitored
-
6:20
characteristics of mri lesions allowing active surveillance and how to monitor
-
20:23
active surveillance criteria and follow-up protocol
-
25:24
active surveillance in 2021 part 2: imaging and biomarkers
-
8:41
mri-targeted biopsies and overdiagnosis in prostate cancer
-
21:01
non-invasive methods to image the brain clearance system
-
9:25
gleason 3 4 active surveillance, psma alternatives, and more | answering youtube comments #46 | pcri
-
28:33
active surveillance results and implications of prospective studies
-
20:50
active surveillance 2021 - from bench to bedside
-
23:37
active surveillance who is the right patient and what is the right protocol
-
12:46
what role do markers play in establishing active surveillance or definitive care?
-
10:50
urologic perspective on the current and emerging role of multi-modality imaging and radiogenomics
-
11:43
current and emerging role of radiogenomics in risk assessment for focal therapy
-
9:27
role of mr-targeted prostate biopsy in active surveillance
-
26:28
active surveillance from biology to bedside
-
17:45
point-counterpoint: oncotype dx genomic prostate score in active surveillance – canary pass study
-
24:04
active surveillance or focal therapy as primary management
-
2:40
ask the expert: how often should patients on active surveillance be biopsied and imaged?
-
9:02
focal therapy for localized pca: is there a middle ground between active surveillance and treatment
-
11:20
evaluation and management of localized and recurrent prostate cancer: genetic cancer profiling